Get started
BIOGEN INCBIOGEN INCBIOGEN INC

BIOGEN INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

BIIB chart


Full chart

Key facts today


The European Commission has approved Biogen's drug Leqembi for early-stage Alzheimer's, targeting mild cognitive impairment in patients with specific genetic markers and amyloid beta protein clumps.
Goldman Sachs has adjusted Biogen's price target to $219 from $245 while maintaining a 'Buy' rating on the stock.
Analyze the impactAnalyze the impact

BIIB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪14.84 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
10.10
Basic EPS (TTM)
10.84 EUR
Net income (FY)
‪1.58 B‬ EUR
Revenue (FY)
‪8.95 B‬ EUR
Shares float
‪145.62 M‬
Beta (1Y)
0.49

Employees


Employees (FY)
‪7.61 K‬
Change (1Y)
+35 +0.46%
Revenue / Employee (1Y)
‪1.18 M‬ EUR
Net income / Employee (1Y)
‪207.32 K‬ EUR

About Biogen Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher A. Viehbacher
Website
biogen.com
Headquarters
Cambridge
Founded
1978
FIGI
BBG00GQ6S010
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BIIB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BIIB highest yielding bonds


BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050
Yield to maturity
7.81%
Maturity date
May 1, 2050
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
7.74%
Maturity date
Feb 15, 2051
US9062XAD5
BIOGEN INC. 15/45
Yield to maturity
6.75%
Maturity date
Sep 15, 2045
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030
Yield to maturity
5.45%
Maturity date
May 1, 2030
IDPC
BIOGEN INC. 15/25
Yield to maturity
5.12%
Maturity date
Sep 15, 2025
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
4.65%
Maturity date
Feb 15, 2051

See all BIIB bonds 

Sparks


Curated watchlists where BIIB is featured.

See all sparks 


Check out other big names from the same industry as BIIB.

Frequently Asked Questions


The current price of BIIB is 104.56 EUR — it has increased by 4.44% in the past 24 hours. Watch BIOGEN INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange BIOGEN INC stocks are traded under the ticker BIIB.
BIIB stock has fallen by −4.25% compared to the previous week, the month change is a −19.88% fall, over the last year BIOGEN INC has showed a −44.11% decrease.
We've gathered analysts' opinions on BIOGEN INC future price: according to them, BIIB price has a max estimate of 301.26 EUR and a min estimate of 110.11 EUR. Watch BIIB chart and read a more detailed BIOGEN INC stock forecast: see what analysts think of BIOGEN INC and suggest that you do with its stocks.
BIIB reached its all-time high on Jun 10, 2021 with the price of 348.10 EUR, and its all-time low was 98.96 EUR and was reached on Apr 9, 2025. View more price dynamics on BIIB chart.
See other stocks reaching their highest and lowest prices.
BIIB stock is 2.30% volatile and has beta coefficient of 0.49. Track BIOGEN INC stock price on the chart and check out the list of the most volatile stocks — is BIOGEN INC there?
Today BIOGEN INC has the market capitalization of ‪15.38 B‬, it has decreased by −10.70% over the last week.
Yes, you can track BIOGEN INC financials in yearly and quarterly reports right on TradingView.
BIOGEN INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
BIIB earnings for the last quarter are 3.32 EUR per share, whereas the estimation was 3.22 EUR resulting in a 3.26% surprise. The estimated earnings for the next quarter are 3.04 EUR per share. See more details about BIOGEN INC earnings.
BIOGEN INC revenue for the last quarter amounts to ‪2.37 B‬ EUR, despite the estimated figure of ‪2.33 B‬ EUR. In the next quarter, revenue is expected to reach ‪2.07 B‬ EUR.
BIIB net income for the last quarter is ‪257.72 M‬ EUR, while the quarter before that showed ‪348.93 M‬ EUR of net income which accounts for −26.14% change. Track more BIOGEN INC financial stats to get the full picture.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has ‪7.61 K‬ employees. See our rating of the largest employees — is BIOGEN INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC EBITDA is ‪2.70 B‬ EUR, and current EBITDA margin is 30.19%. See more stats in BIOGEN INC financial statements.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC stock shows the strong sell signal. See more of BIOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.